Menu Home About Albireo Senior Management Board of Directors Values Programs Pipeline A4250 A3384 Elobixibat Our Science Bile Acids And IBAT Inhibition Pediatric Cholestatic Liver Disease Indications Progressive Familial Intrahepatic Cholestasis (PFIC) Biliary Atresia Adult Liver Disease Indications Nonalcoholic Steatohepatitis (NASH) Gastrointestinal Indications Chronic Idiopathic Constipation (CIC) Bile Acid Malabsorption (BAM) Publications Partners Investors Contact A Leader in Bile Acid Biology and the Development of Novel Bile Acid Modulators Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to address unmet needs in orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a third product candidate for which an application for regulatory approval has been submitted in Japan. Albireo’s lead product candidate, A4250, is nearing initiation of Phase 3 clinical development in patients with progressive familial intrahepatic cholestasis (PFIC). For more information, read Albireo’s corporate backgrounder. Albireo to Present at Investor Conferences in September September 19, 2017 Albireo Reports Second Quarter 2017 Financial Results August 21, 2017 Albireo to Present at Wedbush PacGrow Healthcare Conference August 8, 2017 Albireo Homepage Menu About Albireo Programs Our Science Partners Investors Contact Copyright © 2017 Albireo